Why Actinium Pharma $ATNM Offers Favorable Risk/Reward Profile

2016 has so far turned out to be a challenging year for the biotechnology sector. actinium logo The sector saw two sell-offs in 2015 but managed to finish the year on a strong note. However, the start of this year can be termed as nothing but disastrous for the sector. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) dropped to a 52-week low earlier this year. However, the sell-off has created an excellent opportunity to buy. Read more